Comparison of Prices for Commonly Administered Drugs in Employer-Sponsored Insurance Relative to Medicare.
作者信息
Chang Jessica Y, Sen Aditi P
机构信息
Health Care Cost Institute, Washington, DC.
出版信息
JAMA Health Forum. 2023 Feb 3;4(2):e225422. doi: 10.1001/jamahealthforum.2022.5422.
Abstract
摘要
相似文献
1
Comparison of Prices for Commonly Administered Drugs in Employer-Sponsored Insurance Relative to Medicare.
JAMA Health Forum. 2023 Feb 3;4(2):e225422. doi: 10.1001/jamahealthforum.2022.5422.
2
Trends underlying employer-sponsored health insurance growth for Americans younger than age sixty-five.
Health Aff (Millwood). 2013 Oct;32(10):1715-22. doi: 10.1377/hlthaff.2013.0556.
3
Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Am J Manag Care. 2020 Sep;26(9):388-394. doi: 10.37765/ajmc.2020.88489.
4
Out-of-pocket health care expenditures, by insurance status, 2007-10.
Health Aff (Millwood). 2015 Jan;34(1):111-6. doi: 10.1377/hlthaff.2014.0422.
5
Sources of Geographic Variation in Health Care Spending Among Individuals With Employer Sponsored Insurance.
Med Care Res Rev. 2021 Oct;78(5):548-560. doi: 10.1177/1077558720926095. Epub 2020 Jul 6.
6
Medicare spending by beneficiaries with various types of supplemental insurance.
Med Care Res Rev. 1999 Jun;56(2):137-55. doi: 10.1177/107755879905600202.
7
The effect of Medicare supplemental insurance on Medicare expenditures.
Int J Health Care Finance Econ. 2002 Jun;2(2):137-62. doi: 10.1023/a:1019978531869.
8
Supplemental coverage associated with more rapid spending growth for Medicare beneficiaries.
Health Aff (Millwood). 2013 May;32(5):873-81. doi: 10.1377/hlthaff.2012.1230.
9
The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization.
Health Serv Res. 2015 Jun;50(3):883-96. doi: 10.1111/1475-6773.12262. Epub 2014 Nov 27.
10
Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease.
JAMA. 2001 Oct 10;286(14):1732-9. doi: 10.1001/jama.286.14.1732.
引用本文的文献
1
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
JAMA Health Forum. 2024 Mar 1;5(3):e235429. doi: 10.1001/jamahealthforum.2023.5429.
2
Association between changes in prices and out-of-pocket costs for brand-name clinician-administered drugs.
Health Serv Res. 2024 Dec;59(6):e14279. doi: 10.1111/1475-6773.14279. Epub 2024 Jan 21.
本文引用的文献
1
Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance.
JAMA Intern Med. 2022 Jun 1;182(6):603-611. doi: 10.1001/jamainternmed.2022.1022.
2
Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014.
JAMA Oncol. 2018 Apr 1;4(4):580-581. doi: 10.1001/jamaoncol.2017.5544.
Zotero 插件